共 174 条
[1]
Malaisse WJ(1995)Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: the rreglitinide family Horm Metab Res 27 263-6
[2]
Dornhorst A(2001)Insulinotropic rreglitinide analogues Lancet 358 1709-16
[3]
Culy CR(2001)Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus Drugs 61 1625-60
[4]
Jarvis B(2003)Clinical significance, pathogenesis, and management of postprandial hyperglycemia Arch Intern Med 163 1306-16
[5]
Gerich IE(2001)Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence Diabetologia 44 2107-14
[6]
Bonora E(1997)Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes Diabetes Care 20 1822-6
[7]
Muggeo M(2000)Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbAlc Diabetes Care 23 1236-41
[8]
Avignon A(1996)Risk factors for myocardial infarction and death in newly detected NIDDM: the Dia betes Intervention Study, 11-year follow-up Diabetologia 39 1577-83
[9]
Radauceanu A(1999)Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study Diabetes Care 22 920-4
[10]
Monnier L(1998)Stimilation of insulin release by repaglinde and glibenclamide involves both common and distinct processes Diabetes 47 345-51